Jena oncologist receives Thuringian research award for CML studies
Prof. Dr. Andreas Hochhaus from Jena University Hospital was awarded the Thuringian Research Award 2025 in the category “applied research” for his clinical studies on chronic myeloid leukemia (CML). The prize, which is endowed with 25,000 euros and shares with a team from Nordhausen University of Applied Sciences, honors his work on new tyrosine kinase inhibitors.
Hochhaus led the ASC4FIRST study, which tested the active ingredient asciminib in 111 centers worldwide on over 400 CML patients. Asciminib showed a faster and more effective reduction of leukemia with fewer side effects compared to standard therapy, which forms the basis for its approval as a first-line treatment. CML, the second most common chronic leukemia, affects about 1200 people in Germany every year.

Hochhaus has been researching the molecular mechanisms and therapeutic approaches of CML for over 20 years. He coordinates the German CML Alliance and is co-director of the Central German Cancer Center. The award emphasizes the importance of clinical research at university hospitals for innovative patient care.
Matching:
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia | New England Journal of Medicine
Editor: X-Press Journalistenbüro GbR
Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.




